Top Markets
#1 MowCat MowCat +369.83%
#2 龙虾 (Lobster) 龙虾 (Lobster) +66.68%
#3 SODAX SODAX +47.27%
#4 Cortex Cortex +34.03%
#5 OpenEden OpenEden +24.18%
#6 DexNet DexNet +23.19%
#7 Akedo Akedo +16.57%
#8 wojak wojak +16.21%
#9 Magma Finance Magma Finance +15.83%
#10 MANTRA MANTRA +15.75%
Coin of the day
MowCat MowCat
Setări
Limbă
ROMâNă
Monedă
USD
Temă
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Rang în acțiuni #7188
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Preț acțiune
$38.45
Capitalizare de piață
$1.68B
Schimbare (1 zi)
-1.24%
Schimbare (1 an)
50.36%
Țară
KR
Tranzacționează D&D Pharmatech (347850)

Categorie

Healthcare
Raport P/E pentru D&D Pharmatech (347850)
Raport P/E la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor D&D Pharmatech, raportul P/E actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/E de 0.
Istoricul raportului P/E pentru D&D Pharmatech din 2026 până în 2026
Raportul P/E la sfârșitul fiecărui an
An Raport P/E Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raportul P/E pentru companii similare sau concurenți
Companie P/E Ratio Diferență P/E Ratio Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cum interpretezi un P/E ratio?

Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.

Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.

Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.